Physician profile
Matthew K Mo
NPI 1306919899
$7,884.80
in general payments reported to CMS, 2019-2025
25 companies · $474 in 2025
The $474 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,772 · 2020: $782 · 2021: $561 · 2022: $451 · 2023: $489 · 2024: $356 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,319.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,663.62 | 2019-2025 | Repatha, Otezla, Repatha |
| Amarin Pharma, INC. | $868.45 | 2019-2021 | |
| Abbvie INC. | $696.36 | 2019-2025 | |
| Gilead Sciences, INC. | $677.80 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $654.71 | 2019-2024 | Farxiga |
| Esperion Therapeutics, INC. | $519.06 | 2020-2024 | Nexlizet, Nexletol |
| Sanofi-Aventis U.S. LLC | $425.21 | 2019 | |
| Novartis Pharmaceuticals Corporation | $320.58 | 2019-2023 | |
| Radius Health, INC. | $313.51 | 2019 | |
| Allergan, INC. | $241.71 | 2019-2020 | |
| Glaxosmithkline, LLC. | $237.76 | 2020-2025 | Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $211.30 | 2019 | |
| Abbott Laboratories | $195.12 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $127.38 | 2019 | |
| Ironwood Pharmaceuticals, INC | $119.17 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $116.66 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.38 | 2019 | |
| Pfizer INC. | $102.22 | 2020-2024 | |
| Ibsa Pharma INC. | $98.26 | 2022-2023 | Tirosint, Licart |
| Novo Nordisk INC | $62.41 | 2021-2025 | Rybelsus, Ozempic |
| Alk-Abello, INC | $30.71 | 2025 | Ragwitek, Grastek, Odactra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.22 | 2022 | |
| Eyevance Pharmaceuticals LLC | $22.97 | 2021 | |
| Hikma Pharmaceuticals USA | $22.97 | 2021 | |
| Scilex Pharmaceuticals INC. | $16.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Mo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.